Pamrevlumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pamrevlumab
Monoclonal antibody
Type?
SourceHuman
TargetCTGF
Clinical data
SynonymsFG-3019
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10018N1718O2086S48
Molar mass147.0 g/mol g·mol−1

Pamrevlumab (INN[1]) (FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.

This drug was developed by FibroGen, Inc.[2]

References[edit]

  1. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.